Cargando…
Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to tre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407137/ https://www.ncbi.nlm.nih.gov/pubmed/30736463 http://dx.doi.org/10.3390/cancers11020195 |
_version_ | 1783401478974603264 |
---|---|
author | Kohlenberg, Jacob Welch, Brian Hamidi, Oksana Callstrom, Matthew Morris, Jonathan Sprung, Juraj Bancos, Irina Young, William |
author_facet | Kohlenberg, Jacob Welch, Brian Hamidi, Oksana Callstrom, Matthew Morris, Jonathan Sprung, Juraj Bancos, Irina Young, William |
author_sort | Kohlenberg, Jacob |
collection | PubMed |
description | Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to treat metastatic PPGL. We performed a retrospective study of patients age 17 years and older with metastatic PPGL who were treated with ablative therapy at Mayo Clinic, USA, between June 14, 1999 and November 14, 2017. Our outcomes measures were radiographic response, procedure-related complications, and symptomatic improvement. Thirty-one patients with metastatic PPGL had 123 lesions treated during 42 RFA, 23 CRYO, and 4 PEI procedures. The median duration of follow-up was 60 months (range, 0–163 months) for non-deceased patients. Radiographic local control was achieved in 69/80 (86%) lesions. Improvement in metastasis-related pain or symptoms of catecholamine excess was achieved in 12/13 (92%) procedures. Thirty-three (67%) procedures had no known complications. Clavien-Dindo Grade I, II, IV, and V complications occurred after 7 (14%), 7 (14%), 1 (2%), and 1 (2%) of the procedures, respectively. In patients with metastatic PPGL, ablative therapy can effectively achieve local control and palliate symptoms. |
format | Online Article Text |
id | pubmed-6407137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64071372019-03-21 Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma Kohlenberg, Jacob Welch, Brian Hamidi, Oksana Callstrom, Matthew Morris, Jonathan Sprung, Juraj Bancos, Irina Young, William Cancers (Basel) Article Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to treat metastatic PPGL. We performed a retrospective study of patients age 17 years and older with metastatic PPGL who were treated with ablative therapy at Mayo Clinic, USA, between June 14, 1999 and November 14, 2017. Our outcomes measures were radiographic response, procedure-related complications, and symptomatic improvement. Thirty-one patients with metastatic PPGL had 123 lesions treated during 42 RFA, 23 CRYO, and 4 PEI procedures. The median duration of follow-up was 60 months (range, 0–163 months) for non-deceased patients. Radiographic local control was achieved in 69/80 (86%) lesions. Improvement in metastasis-related pain or symptoms of catecholamine excess was achieved in 12/13 (92%) procedures. Thirty-three (67%) procedures had no known complications. Clavien-Dindo Grade I, II, IV, and V complications occurred after 7 (14%), 7 (14%), 1 (2%), and 1 (2%) of the procedures, respectively. In patients with metastatic PPGL, ablative therapy can effectively achieve local control and palliate symptoms. MDPI 2019-02-07 /pmc/articles/PMC6407137/ /pubmed/30736463 http://dx.doi.org/10.3390/cancers11020195 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kohlenberg, Jacob Welch, Brian Hamidi, Oksana Callstrom, Matthew Morris, Jonathan Sprung, Juraj Bancos, Irina Young, William Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma |
title | Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma |
title_full | Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma |
title_fullStr | Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma |
title_full_unstemmed | Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma |
title_short | Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma |
title_sort | efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407137/ https://www.ncbi.nlm.nih.gov/pubmed/30736463 http://dx.doi.org/10.3390/cancers11020195 |
work_keys_str_mv | AT kohlenbergjacob efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma AT welchbrian efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma AT hamidioksana efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma AT callstrommatthew efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma AT morrisjonathan efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma AT sprungjuraj efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma AT bancosirina efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma AT youngwilliam efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma |